(10-([1,1′:3′,1”-terphenyl]-5′-yl)anthracen-9-yl)boronic acid

We are (10-([1,1′:3′,1”-terphenyl]-5′-yl)anthracen-9-yl)boronic acid CAS:1415334-59-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(10-([1,1':3',1''-terphenyl]-5'-yl)anthracen-9-yl)boronic acid
CAS.NO:1415334-59-6
Synonyms:10-(1,1':3',1''-Terphenyl-5'-yl)anthracene-9-boronic Acid
Molecular Formula:C32H23BO2
Molecular Weight:450.33482
 
Specification:
Appearance:Yellow crystalline powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

(10-([1,1':3',1''-terphenyl]-5'-yl)anthracen-9-yl)boronic acid


Related News: The insulin-only and bihormonal configurations may be helpful in diabetes.9-bromo-1-nonanol CAS:55362-80-6 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.2-amino-5-metilpiridina CAS:1603-41-4 As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.tert-Butyl (4R-cis)-6-[(acetyloxy)methyl]-2,2-dimethyl-1,3-dioxane-4-acetate From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
4-Cyanobenzyl bromide View Details
2-Fluoro-4-(trifluoromethyl)benzaldehyde View Details
1,7-Dichloroheptane View Details
2,4-Difluoropyridine manufacturer (S)-(-)-3-(Benzoylthio)-2-methylpropanoic acid manufacturer N-Ac-D,L-Phg-OH manufacturer 2-Cyanobenzyl chloride manufacturer 2-Hydroxy-4-methoxybenzaldehyde manufacturer